Recombinant Staphylococcus aureus Delta-aminolevulinic acid dehydratase (hemB)

What is the biochemical function of Delta-aminolevulinic acid dehydratase (HemB) and its role in S. aureus metabolism?

During infection, S. aureus experiences varying intracellular heme concentrations. The bacterium has developed multiple strategies to maintain heme homeostasis, including the HssRS two-component system that activates the expression of the heme responsive transporter (HrtAB) to alleviate heme toxicity . HemB is part of this complex machinery that allows S. aureus to adapt to different microenvironments during infection, supporting its pathogenic lifestyle and survival within the host.

Research has demonstrated that disruption of hemB function leads to significant metabolic alterations, resulting in the small-colony variant (SCV) phenotype characterized by slow growth, decreased pigment formation, and altered virulence factor expression .

How can researchers generate and validate stable S. aureus hemB mutants for experimental studies?

Generation of site-directed hemB mutants requires precise genetic manipulation through homologous recombination. The established methodology includes:

• PCR amplification of the hemB gene from chromosomal DNA of S. aureus using primers containing appropriate restriction sites (e.g., BamHI and KpnI)

• Cloning the amplified gene (~1,084-bp DNA fragment) into a suitable vector (e.g., pUC19)

• Inserting an antibiotic resistance cassette (e.g., ermB) into the hemB gene

• Transferring the construct to a temperature-sensitive shuttle vector (e.g., pBT9)

• Transforming S. aureus with the construct and selecting for mutants using growth at nonpermissive temperature and antibiotic selection (erythromycin)

• Confirming the mutation through PCR, sequencing, and phenotypic characterization

Validation of successful hemB mutants involves demonstrating the following characteristics:

The SCV phenotype should be reversed by either hemin supplementation (1-4 μg/ml) or genetic complementation with intact hemB, confirming that the observed phenotypes are specifically due to hemB inactivation .

What phenotypic characteristics distinguish hemB mutants from wild-type S. aureus, and how are these quantitatively assessed?

The hemB mutants exhibit distinct characteristics that can be reliably quantified through various experimental approaches:

Growth Characteristics and Colony Morphology

After 24 hours of incubation on agar plates (TSA or chemically defined medium), hemB mutants form small colonies (approximately 0.1-0.3 mm in diameter) compared to wild-type colonies (2-3 mm). Growth curves measured by optical density (OD578) demonstrate significantly slower growth rates, with doubling times of 120-180 minutes for hemB mutants versus approximately 30 minutes for wild-type strains .

Hemolytic Activity Assessment

Hemolytic activity can be quantified spectrophotometrically by measuring hemoglobin released from rabbit erythrocytes. The procedure involves:

• Growing bacteria overnight in TSB to late logarithmic phase

• Pelleting cells by centrifugation (1,200 × g for 5 minutes)

• Incubating bacterial suspensions with erythrocytes

• Measuring released hemoglobin spectrophotometrically

hemB mutants typically show <10% of the hemolytic activity of wild-type strains. This reduced hemolytic capacity can be partially restored by hemin supplementation (1 μg/ml) or fully restored in plasmid-complemented mutants .

Virulence Factor Expression

Northern blot analysis reveals that hemB mutants have significantly reduced transcription of key virulence genes:

• Alpha-toxin (hla): Transcription is high in wild-type S. aureus in early and late stationary phase but undetectable in hemB mutants

• Protein A (spa): Expression is altered in hemB mutants but detectable when complemented with plasmid or grown with hemin

Western blot analysis confirms these findings at the protein level, demonstrating dramatically reduced virulence factor production in hemB mutants compared to wild-type strains .

How does the intracellular persistence of hemB mutants differ from wild-type S. aureus?

hemB mutants demonstrate enhanced intracellular persistence compared to wild-type strains, particularly within endothelial cells. This phenomenon can be experimentally assessed using bovine aortic endothelial cell models .

Experimental Design for Assessing Intracellular Persistence

The methodology for quantifying intracellular persistence includes:

• Co-incubating bacteria (hemB mutant, wild-type, and complemented strains) with endothelial cells for 3.5 hours

• Treating with lysostaphin (20-30 minutes) to eliminate extracellular bacteria

• Washing cells and continuing incubation for desired timepoints

• Lysing cells and quantifying intracellular bacteria by plating

Research Findings on Intracellular Survival

Studies demonstrate that hemB mutants show significantly higher numbers following the initial co-incubation and lysostaphin treatment compared to wild-type strains. This enhanced persistence is attributed to decreased alpha-toxin production, which prevents endothelial cell damage and maintains the intracellular niche .

Importantly, both the plasmid-complemented mutant and the hemin-supplemented hemB mutant demonstrate reduced intracellular persistence similar to the wild-type strain, confirming that the persistence phenotype is specifically linked to hemB inactivation .

What molecular mechanisms enable hemB mutants to persist intracellularly?

Multiple molecular mechanisms contribute to the enhanced intracellular persistence of hemB mutants:

Reduced Cytolytic Toxin Production

Northern blot analysis demonstrates that hemB mutants have undetectable levels of alpha-toxin (hla) mRNA in late stationary phase, whereas the transcript is abundant in wild-type and complemented strains . The absence of alpha-toxin production prevents damage to host cells, allowing bacteria to maintain their intracellular niche without causing cell lysis.

Altered Protein A Expression

Protein A (encoded by spa) shows modified expression patterns in hemB mutants compared to wild-type strains. While spa message is detectable in wild-type S. aureus throughout growth phases, in the hemB mutant, it is only detectable when the strain is complemented with plasmid or grown with hemin . This alteration in important surface proteins may contribute to evading host immune recognition.

Metabolic Adaptations

The defect in the electron transport system due to impaired heme biosynthesis leads to significant metabolic adaptations:

• Reduced energy production

• Slower growth rate

• Altered central metabolism

• Modified stress responses

These adaptations create a persistent phenotype that can withstand the intracellular environment while evading host defenses and antibiotic action .

How can hemin supplementation restore wild-type phenotype in hemB mutants?

Hemin supplementation bypasses the metabolic block caused by hemB mutation by providing an exogenous source of heme for cytochrome production and electron transport.

Optimal Hemin Supplementation Conditions

Research demonstrates that different concentrations of hemin (1-4 μg/ml) should be tested to determine optimal supplementation conditions. The mutant can be inoculated to OD578 of 0.05 and grown with shaking at 150 rpm at 37°C in either complex medium (TSB) or chemically defined medium (CDM) .

Phenotypic Restoration by Hemin

Hemin supplementation at appropriate concentrations results in:

• Increased growth rate (approaching wild-type doubling times)

• Restoration of pigment production

• Partial recovery of hemolytic activity

• Detectable transcription of virulence genes (including hla and spa)

How do hemB mutations affect antibiotic susceptibility patterns in S. aureus?

hemB mutations significantly alter antibiotic susceptibility profiles through multiple mechanisms related to the SCV phenotype:

Aminoglycoside Resistance

The hemB mutants demonstrate resistance to aminoglycosides, which is a characteristic feature of electron-transport-defective strains . This resistance occurs because aminoglycoside uptake requires membrane potential, which is reduced in hemB mutants due to impaired electron transport.

Methodological Considerations for Susceptibility Testing

When testing antimicrobial efficacy against hemB mutants, several important considerations must be addressed:

• Extended incubation times (48-72h) may be required for accurate MIC determination due to slower growth

• Hemin supplementation should be tested as a control to confirm phenotype reversibility

• Both extracellular and intracellular antibiotic efficacy should be evaluated due to the enhanced intracellular persistence of hemB mutants

Clinical Implications

The altered susceptibility profile of hemB mutants has significant clinical implications, particularly for persistent and recurrent infections. Standard antibiotic treatments may fail to eradicate intracellular SCVs, leading to chronic or relapsing infections despite apparent initial clinical response .

What techniques can be used to study heme binding properties of purified recombinant HemB?

Investigating the heme binding properties of HemB requires purification of recombinant protein and specialized biochemical assays:

Recombinant HemB Purification

Recombinant S. aureus HemB can be expressed with a His-tag in expression systems such as Escherichia coli or yeast . The protein can then be purified using affinity chromatography. Commercial sources offer recombinant HemB proteins with >90% purity suitable for enzymatic and binding studies .

Heme Binding Assessment

To determine whether S. aureus GtrR (another heme biosynthetic enzyme) binds heme in vitro, researchers have purified recombinantly expressed protein from E. coli and assessed binding properties . Similar approaches can be applied to HemB:

• UV-visible spectroscopy to detect characteristic spectral shifts upon heme binding

• Isothermal titration calorimetry to quantify binding affinity

• Site-directed mutagenesis of potential heme-binding residues to identify critical amino acids involved in interaction

Research findings indicate that heme binding to biosynthetic enzymes may play a regulatory role in controlling enzyme activity and stability, contributing to heme homeostasis in S. aureus .

How can complementation assays verify the specific effects of hemB mutation?

Complementation assays are essential for confirming that observed phenotypes are specifically due to hemB inactivation rather than polar effects or secondary mutations:

Genetic Complementation Methodology

The established approach includes:

• PCR amplification of the intact hemB gene

• Cloning into an expression vector with an inducible promoter (e.g., xylose-inducible promoter in pCX19)

• Transforming the hemB mutant with this construct

• Inducing expression with the appropriate compound (xylose)

• Assessing phenotypic reversal

Cross-Species Complementation

Complementation can also be performed across species to demonstrate functional conservation:

• The PCR-amplified S. aureus hemB gene can be cloned and expressed in E. coli hemB mutant (RP523)

• Successful transformation results in normal growth in E. coli

• Curing E. coli RP523 of the plasmid restores the small-colony phenotype

These cross-species complementation studies confirm the functional conservation of HemB across bacterial species and provide additional validation of the specific role of hemB in the observed phenotypes.

What is the relationship between hemB function and global gene expression in S. aureus?

Disruption of hemB function leads to profound changes in global gene expression beyond the direct effects on heme biosynthesis:

Virulence Factor Regulation

Northern blot analysis demonstrates that hemB mutants have significantly altered expression of key virulence factors:

• Alpha-toxin (hla): Transcript undetectable in hemB mutants but abundant in wild-type in stationary phase

• Protein A (spa): Expression pattern altered in hemB mutants

These changes suggest that electron transport deficiency disrupts normal virulence gene regulation, potentially through altered energy metabolism and disruption of regulatory networks.

Regulatory Cascades Affected

The reduced expression of virulence factors in hemB mutants may involve multiple regulatory mechanisms:

• Altered activity of global regulators (e.g., Agr, SarA)

• Disrupted quorum sensing due to altered growth dynamics

• Modified stress responses due to metabolic adaptation

• Post-translational regulation through kinases and phosphatases

Research has linked cell growth arrest to the modulation of heme levels through post-translational regulation of heme biosynthetic enzymes by the kinase Stk1 and the phosphatase Stp1 , suggesting complex regulatory networks that respond to alterations in cellular heme status.

Understanding these global regulatory effects is crucial for developing strategies to target persistent infections associated with the SCV phenotype.